FATE Q1 2021 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+343.0% YoY

Gross Profit

-$34M-302.5% margin

Operating Income

-$46M-414.7% margin

Net Income

-$45M-404.7% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-29.9%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$31M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$256M

Stockholders' Equity

$790M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$3M	+343.0%
Gross Profit	-$34M	-$27M	-26.0%
Operating Income	-$46M	-$34M	-34.0%
Net Income	-$45M	-$34M	-34.5%

Revenue Segments

Upfront Fee And Equity Premium

$2M100%